Fractyl Health, Inc. has announced the entry into a significant underwriting agreement with Ladenburg Thalmann & Co. Inc. This agreement pertains to the underwritten offering, issuance, and sale of 19,047,619 shares of the company's common stock, alongside accompanying Tranche A and Tranche B Warrants, all priced at a combined offering of $1.05 per share with accompanying warrants. The net proceeds from this offering will be utilized to bolster Fractyl Health's Revita and Rejuva pipeline programs and for general corporate purposes. Additionally, Fractyl Health has committed to holding a special stockholder meeting to seek approval for the Tranche B Warrants within 60 days of closing the offering, with strong backing from the company's board and key stakeholders.